{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:18:03Z","timestamp":1781914683877,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.mayocp.2016.01.015","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T06:15:20Z","timestamp":1459491320000},"page":"456-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome"],"prefix":"10.1016","volume":"91","author":[{"given":"Fan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Dong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11-12","key":"10.1016\/j.mayocp.2016.01.015_bib1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1365-2036.2005.02696.x","article-title":"Review article: the role of serotonergic agents in the treatment of patients with primary chronic constipation","volume":"22","author":"Cash","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.mayocp.2016.01.015_bib2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-2036.2007.03320.x","article-title":"Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety","volume":"25","author":"Johanson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2016.01.015_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14740338.2014.902932","article-title":"The safety of novel drugs used to treat irritable bowel syndrome","volume":"13","author":"Mozaffari","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.mayocp.2016.01.015_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjmed.2011.08.026","article-title":"Evaluation of harm in the pharmacotherapy of irritable bowel syndrome","volume":"125","author":"Shah","year":"2012","journal-title":"Am J Med"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2016.01.015_bib5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mayocp.2016.01.015_bib6","first-page":"191","article-title":"A\u00a0critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly","volume":"8","author":"Gras-Miralles","year":"2013","journal-title":"Clin Interv Aging"},{"issue":"5","key":"10.1016\/j.mayocp.2016.01.015_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ajg.2015.106","article-title":"A\u00a0randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain","volume":"110","author":"Jamal","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.01.015_bib8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1345\/aph.1K047","article-title":"Lubiprostone: a chloride channel activator for treatment of chronic constipation","volume":"41","author":"Ambizas","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.mayocp.2016.01.015_bib9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/17425255.4.8.1091","article-title":"Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders","volume":"4","author":"Ginzburg","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.01.015_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-200666060-00015","article-title":"Lubiprostone","volume":"66","author":"McKeage","year":"2006","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.mayocp.2016.01.015_bib11","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/ajg.2010.200","article-title":"Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome","volume":"105","author":"Wong","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.01.015_bib12","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mayocp.2016.01.015_bib13","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","year":"2011"},{"issue":"1","key":"10.1016\/j.mayocp.2016.01.015_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation","volume":"103","author":"Johanson","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.01.015_bib15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2982.2011.01668.x","article-title":"Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study","volume":"23","author":"Fukudo","year":"2011","journal-title":"Neurogastroenterol Motil"},{"issue":"8","key":"10.1016\/j.mayocp.2016.01.015_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2016.01.015_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome\u2014results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.mayocp.2016.01.015_bib18","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10620-009-1068-x","article-title":"Efficacy and safety of lubiprostone in patients with chronic constipation","volume":"55","author":"Barish","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.mayocp.2016.01.015_bib19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1365-2982.2011.01776.x","article-title":"Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome","volume":"23","author":"Whitehead","year":"2011","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"10.1016\/j.mayocp.2016.01.015_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cgh.2014.08.026","article-title":"Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation","volume":"13","author":"Fukudo","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.01.015_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.mayocp.2016.01.015_bib22","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2016.01.015_bib23","unstructured":"SIB-0431: Efficacy and safety of lubiprostone in patients with irritable bowel syndrome with Constipation. ClinicalTrials.gov., https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00380250?term=NCT00380250&rank=1. Accessed January 31, 2015."},{"key":"10.1016\/j.mayocp.2016.01.015_bib24","unstructured":"SIB-0432: Efficacy and safety of lubiprostone in patients with irritable bowel syndrome with Constipation. ClinicalTrials.gov., https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00399542?term=NCT00399542&rank=1. Accessed January 31, 2015."},{"issue":"5","key":"10.1016\/j.mayocp.2016.01.015_bib25","doi-asserted-by":"crossref","first-page":"G942","DOI":"10.1152\/ajpgi.00264.2005","article-title":"Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers","volume":"290","author":"Camilleri","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.01.015_bib26","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/pme.12437","article-title":"A\u00a0randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain","volume":"15","author":"Cryer","year":"2014","journal-title":"Pain Med"},{"issue":"1418","key":"10.1016\/j.mayocp.2016.01.015_bib27","first-page":"47","article-title":"Lubiprostone (Amitiza) for opioid-induced constipation","volume":"55","year":"2013","journal-title":"Med Lett Drugs Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2016.01.015_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14656566.2011.566559","article-title":"Lubiprostone for the treatment of opioid-induced bowel dysfunction","volume":"12","author":"Wong","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.mayocp.2016.01.015_bib29","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/ajg.2013.169","article-title":"Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.01.015_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/MPG.0000000000000268","article-title":"Lubiprostone in pediatric functional constipation","volume":"58","author":"Faure","year":"2014","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.mayocp.2016.01.015_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MPG.0000000000000176","article-title":"Lubiprostone for the treatment of functional constipation in children","volume":"58","author":"Hyman","year":"2014","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.mayocp.2016.01.015_bib32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1543-5946(10)80003-0","article-title":"A\u00a0review of laxative therapies for treatment of chronic constipation in older adults","volume":"8","author":"Fleming","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"issue":"2","key":"10.1016\/j.mayocp.2016.01.015_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3748\/wjg.v19.i2.299","article-title":"Lubiprostone induced ischemic colitis","volume":"19","author":"Sherid","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.01.015_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/17425255.2013.876410","article-title":"Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome","volume":"10","author":"Raschi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616000707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616000707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T17:20:07Z","timestamp":1536859207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616000707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0025619616000707"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.01.015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726266208.793516543","asserted-by":"object"}]},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}